A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
01/2007
01/02/2007	CA2344350C 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
01/02/2007	CA2225628C Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
12/2006
12/29/2006	CA2511158A1 Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy
12/28/2006	WO2006138571A2 Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
12/28/2006	WO2006138038A1 Intralesional treatment of psoriasis
12/28/2006	WO2006137597A1 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
12/28/2006	WO2006137595A1 Prophylactic/therapeutic agent for her2-expressing cancer
12/28/2006	WO2006137514A1 Therapeutic agent for cancer comprising substance capable of inhibiting expression or function of synoviolin as active ingredient and screening method for the therapeutic agent for cancer
12/28/2006	WO2006137510A1 Agent for reduction of bleeding in cerebrovascular disorder
12/28/2006	WO2006137509A1 Cyclic amine derivative containing ppar regulator
12/28/2006	WO2006137421A1 Agent for topical administration
12/28/2006	WO2006137398A1 Therapeutic agent for cancer
12/28/2006	WO2006137377A1 Neuronal regeneration promoter
12/28/2006	WO2006137368A1 Preventive or remedy for glaucoma
12/28/2006	WO2006137341A1 Agent for visualizing vitreous body
12/28/2006	WO2006137314A1 Radial brush
12/28/2006	WO2006136841A1 Multiple sclerosis therapy and diagnosis
12/28/2006	WO2006136175A2 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
12/28/2006	WO2006136033A1 Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
12/28/2006	WO2006108670A3 Use of cd25 antibodies in immunotherapy
12/28/2006	WO2006099480A3 Stress proteins and peptides and methods of use thereof
12/28/2006	WO2006042733A3 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
12/28/2006	WO2005123093A3 Ophthalmic formulations including selective alpha 1 antagonists
12/28/2006	WO2005097193A3 Sequential sprm/progestin treatment
12/28/2006	WO2005079271A3 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
12/28/2006	WO2004041067A3 Prevention and treatment of synucleinopathic disease
12/28/2006	US20060293391 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
12/28/2006	US20060293334 Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase
12/28/2006	US20060293323 Therapeutic Combinations of erb B Kinase Inhibitors and Antineoplastic Therapies
12/28/2006	US20060293312 Method of improved diuresis in individuals with impaired renal function
12/28/2006	US20060293306 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons
12/28/2006	US20060293239 Treatment and Diagnosis of Insulin-Resistant States
12/28/2006	US20060292689 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292638 Sequence #115 as a target for identifying weight modulating compounds
12/28/2006	US20060292548 Using channel protein and immobilized nerve to identify inhibitors of bitter and/or sweet taste preception
12/28/2006	US20060292186 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
12/28/2006	US20060292116 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
12/28/2006	DE102005029468A1 Use of an exogenous or endogenous inhibitor of N-methyltransferase for the manufacture of a medicament for therapy and prophylaxis of Parkinson's syndrome
12/28/2006	CA2678008A1 Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2613257A1 A novel biological substance nesfatin and its related substances and uses thereof
12/28/2006	CA2613253A1 Combination comprising amino alcohol derivatives as immunosuppressants
12/28/2006	CA2613244A1 Vitreous body visualization agent
12/28/2006	CA2613210A1 Multiple sclerosis therapy and diagnosis
12/28/2006	CA2612859A1 Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
12/28/2006	CA2612829A1 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
12/28/2006	CA2612347A1 Methods for treating dermatitis using mutant human il-4 compositions
12/28/2006	CA2612309A1 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
12/28/2006	CA2610281A1 Therapeutic agent for cancer
12/27/2006	EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof
12/27/2006	EP1736547A1 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation
12/27/2006	EP1736544A1 Gm1 PROMOTER AND USE THEREOF
12/27/2006	EP1736173A1 Damaged tissue therapeutic agent and therapeutic method
12/27/2006	EP1736172A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like
12/27/2006	EP1736170A2 Agent for treating allergic or hypersensitivity condition
12/27/2006	EP1736168A1 Protease inhibitor and preventives or remedies for diseases
12/27/2006	EP1736155A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
12/27/2006	EP1736153A2 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd)
12/27/2006	EP1736152A2 Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds
12/27/2006	EP1736151A2 Pharmaceutical composition for the therapy of lower urinary tract symptoms
12/27/2006	EP1735328A1 Protein c and endothelial protein c receptor polymorphisms as indicators of subject outcome
12/27/2006	EP1735057A2 Method and compositions for treatment of chronic neuropathic pain
12/27/2006	EP1735003A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
12/27/2006	EP1735002A2 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
12/27/2006	EP1735001A2 Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
12/27/2006	EP1735000A2 Method for augmenting b cell depletion
12/27/2006	EP1734999A2 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
12/27/2006	EP1734975A1 Herbal therapy for the treatment of food allergy
12/27/2006	EP1734966A2 Piperizinylpiperidine derivatives as chemokine receptor antagonists
12/27/2006	EP1734958A1 Methods for the treatment of hypertension
12/27/2006	EP1734955A2 Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
12/27/2006	EP1734953A1 Co-formulations of kits of bioactive agents
12/27/2006	EP1734951A2 Diphenyl-indol-2-on compounds and their use in the treatment of cancer
12/27/2006	EP1734945A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
12/27/2006	EP1534282B1 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
12/27/2006	EP1448559B1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
12/27/2006	EP1440159B1 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
12/27/2006	EP1429843B1 Combination of a pde inhibitor and a leukotriene receptor antagonist
12/27/2006	EP1404704B1 Bridged bicyclic serine protease inhibitors
12/27/2006	EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids
12/27/2006	EP1354047B1 Methods for screening compounds that modulate lipid metabolism
12/27/2006	EP1345895B1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
12/27/2006	EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
12/27/2006	EP1297147B1 Compositions for the diagnosis and treatment of herpes simplex virus infection
12/27/2006	EP1225870B1 Composition and method of cancer antigen immunotherapy
12/27/2006	EP1117437B1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
12/27/2006	EP1105505B1 Compound and method for the prevention and/or the treatment of allergy
12/27/2006	EP1034273B1 Histamine and serotonin binding molecules
12/27/2006	EP0998495B1 Amyloid beta protein (globular assembly and uses thereof)
12/27/2006	EP0918458B1 Antimicrobial treatment for herpes simplex virus and other infectious diseases
12/27/2006	EP0844875B1 Use of basic l-carnitine and acyl derivatives for lowering ceramide levels
12/27/2006	EP0783891B1 Interferon-beta for bone diseases
12/27/2006	CN1886506A Protein expressed in nk cell
12/27/2006	CN1886393A Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
12/27/2006	CN1886157A Pharmaceutical combinations
12/27/2006	CN1886147A Compositions for the treatment of affections of the oral cavity and upper respiratory tract
12/27/2006	CN1886142A Methods and means for modulating lipid metabolism
12/27/2006	CN1883706A Topically applied sustained-release antibiotic preparation
12/27/2006	CN1883478A Pharmaceutical composition for treating hypertension and cardiovascular disease

1 ... 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 ... 1151